PharmEasy sets sights on profit by 2027 with new CEO at the helm
PharmEasy's parent company, API Holdings, has set a clear goal: turn profitable by March 2027.
New CEO Rahul Guha, who stepped in this August, is steering the company with tighter cost controls and a push for higher-margin products.
The aim? To finally move into the black on both EBITDA and net profit (excluding Thyrocare) by March 2027.
What's happening behind the scenes?
Revenue grew slightly to ₹5,872 crore in FY25, and losses dropped by 40%—a big step forward.
While their main online pharmacy business still runs at a loss, their diagnostics arm Thyrocare is making steady profits.
Guha's "One Group" strategy—think more teamwork and smarter buying—has boosted margins by ramping up internal procurement from 40% to 85%.
They're now focusing more on chronic patients who value savings over speed, plus rolling out private label products, at-home vaccinations, and elder care services.
Thanks to these moves, monthly losses have shrunk from ₹50 crore to under ₹2 crore this year.
Why should you care?
PharmEasy is one of India's biggest health tech brands—and they're hustling hard to stay relevant and sustainable.
If you're curious about how startups adapt when times get tough or just want a peek into what it takes for big digital players to survive long-term, this story is worth your scroll.